share_log

iBio Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lynx1 Capital Management LP(9.99%),Weston Nichols(9.99%)

iBio Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals

iBio Inc | SC 13G:超过5%持股股东披露文件
美股SEC公告 ·  2024/04/02 07:28

Moomoo AI 已提取核心信息

On March 26, 2024, iBio Inc, a biotechnology company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission. The filing was made by Lynx1 Capital Management LP, a Delaware-based investment manager, and Weston Nichols, the sole member of Lynx1 Capital Management GP LLC, which is the general partner of the investment manager. The filing indicates that Lynx1 Capital Management LP and Mr. Nichols collectively hold 878,492 shares of iBio Inc's common stock, which includes 278,492 shares issuable upon the exercise of warrants. This represents 9.99% of the company's class of securities, taking into account a beneficial ownership blocker that prevents them from exercising warrants that would result in ownership exceeding 9.99% of the outstanding common stock. The filing asserts that the shares were not acquired with the purpose or effect of changing or influencing the control of iBio Inc.
On March 26, 2024, iBio Inc, a biotechnology company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission. The filing was made by Lynx1 Capital Management LP, a Delaware-based investment manager, and Weston Nichols, the sole member of Lynx1 Capital Management GP LLC, which is the general partner of the investment manager. The filing indicates that Lynx1 Capital Management LP and Mr. Nichols collectively hold 878,492 shares of iBio Inc's common stock, which includes 278,492 shares issuable upon the exercise of warrants. This represents 9.99% of the company's class of securities, taking into account a beneficial ownership blocker that prevents them from exercising warrants that would result in ownership exceeding 9.99% of the outstanding common stock. The filing asserts that the shares were not acquired with the purpose or effect of changing or influencing the control of iBio Inc.
2024年3月26日,生物技术公司iBio Inc成为向美国证券交易委员会提交的附表13G文件的主体。该文件由总部位于特拉华州的投资管理公司Lynx1 Capital Management LP和该投资管理公司的普通合伙人Lynx1 Capital Management GP LLC的唯一成员韦斯顿·尼科尔斯提交。文件显示,Lynx1 Capital Management LP和Nichols先生共持有iBio Inc的878,492股普通股,其中包括行使认股权证时可发行的278,492股股票。这占公司证券类别的9.99%,考虑到受益所有权封锁因素,该封锁使他们无法行使认股权证,导致所有权超过已发行普通股的9.99%。该文件称,收购这些股票的目的或效果不是为了改变或影响iBio Inc的控制权。
2024年3月26日,生物技术公司iBio Inc成为向美国证券交易委员会提交的附表13G文件的主体。该文件由总部位于特拉华州的投资管理公司Lynx1 Capital Management LP和该投资管理公司的普通合伙人Lynx1 Capital Management GP LLC的唯一成员韦斯顿·尼科尔斯提交。文件显示,Lynx1 Capital Management LP和Nichols先生共持有iBio Inc的878,492股普通股,其中包括行使认股权证时可发行的278,492股股票。这占公司证券类别的9.99%,考虑到受益所有权封锁因素,该封锁使他们无法行使认股权证,导致所有权超过已发行普通股的9.99%。该文件称,收购这些股票的目的或效果不是为了改变或影响iBio Inc的控制权。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息